Electroconvulsive therapy (ECT) effective for psychotic recrudescence and suicidality after varenicline adjunctive therapy for smoking cessation in a schizoaffective patient

A review of electroconvulsive therapy in suicidality

Introduction

Suicidal thoughts and behaviors are highly associated with major psychiatric illnesses, including depression, schizophrenia, and substance related disorders.1 Suicide is a major cause of death in individuals with mood disorders, and mortality rates are markedly higher in this patient cohort compared with those without mental illness.2,3 The estimated lifetime rate of suicide in those with schizophrenia, major depressive disorder, and bipolar disorder are 6.0%, 14.6%, and 15.5%, respectively, as compared with 0.72% in the general population.4

Methods

A literature search was conducted for empirical evidence of affect of suicidality with electroconvulsive therapy.

Results

Available evidence suggests electroconvulsive therapy may reduce the risk of suicide in various patient populations.

Discussion

This review seeks to summarize a selection of the pertinent literature describing electroconvulsive therapy's effects on suicidality.

Neuropsychiatric adverse events of varenicline: a systematic review of published reports

INTRODUCTION

Over the past years, the impact of varenicline in patients with mental illness has been debated as serious neuropsychiatric adverse events (AEs) have been reported with varenicline use.

AIM

To identify and summarize published case reports of neuropsychiatric AEs ascribed to varenicline and to determine potential risk factors for these AEs.

METHODS

A literature search of MEDLINE, the Cochrane Library, EMBASE, and PsychInfo database was conducted for case reports concerning the neuropsychiatric AEs of varenicline published in English from 2006 (approval year by the US Food and Drug Administration and the Dutch Medicines Evaluation Board) to January 1, 2012.

RESULTS

We identified 25 published cases. In most reports, patients had been admitted to psychiatric hospitals with serious neuropsychiatric AEs due to varenicline. The average patient age was 46.4 years, and 56% were men; 68% of patients had a psychiatric history. The onset of symptoms started 2 days to 3 months after the initiation of varenicline. One report described completed suicide in a man with no psychiatric history. In most cases (84%), the neuropsychiatric symptoms resolved after the discontinuation of varenicline. Analysis of all reports using the Naranjo causality scale, a method for estimating the probability of adverse drug reactions, indicated probable causality in 76% of the cases and definite causality in 12% of cases.

CONCLUSION

Varenicline is associated with an increased risk of serious neuropsychiatric AEs, especially in patients with a psychiatric illness. It is strongly recommended that varenicline be administered only to mentally stable patients and under close monitoring.